Biotech & Life Sciences IPR Topics.
1. Introduction: Biotech & Life Sciences IP
The biotech and life sciences sector relies heavily on IP protection due to:
High R&D costs
Long development timelines (10–15 years)
Regulatory approvals
Competitive edge in biologics, pharmaceuticals, and diagnostics
IP tools include:
Patents (composition, method of treatment, diagnostic methods)
Data exclusivity (regulatory protection for clinical trial data)
Trade secrets (manufacturing know-how)
Plant variety rights (for genetically engineered plants)
2. Patentability in Biotechnology
Key issues in biotech patenting:
Patentable subject matter: genes, sequences, proteins, cells, diagnostic methods
Novelty and inventive step
Moral and ethical restrictions (especially in EU)
Case 1: Association for Molecular Pathology v Myriad Genetics, Inc. (US, 2013)
Facts:
Myriad patented isolated BRCA1 and BRCA2 genes linked to breast cancer.
Association for Molecular Pathology challenged, claiming genes are products of nature.
Legal Issue:
Are naturally occurring genes patentable once isolated?
Court Reasoning:
Naturally occurring DNA sequences cannot be patented, even if isolated.
cDNA (synthetic DNA) is patentable because it is not naturally occurring.
Decision:
Patents on isolated natural BRCA genes invalid
cDNA patents upheld
Significance:
Sets US standard for gene patentability
Biotech patents must show human intervention and innovation
Case 2: Harvard College v Canada (Commissioner of Patents) (Canada, 2002)
Facts:
Harvard patented genetically modified OncoMouse (cancer research mouse).
Legal Issue:
Are genetically modified higher life forms patentable?
Decision:
OncoMouse patent allowed in US; Canada rejected it as a higher life form cannot be patented.
Significance:
Highlights jurisdictional divergence in biotech patenting
US allows certain life-form patents; EU/Canada more restrictive
Case 3: Biogen Inc v Medeva Plc (UK, 1997)
Facts:
Biogen sued Medeva over DNA sequence patents for interferon beta production.
Legal Issue:
Sufficiency of disclosure in biotech patents (must enable skilled person to reproduce invention)
Court Reasoning:
Patent must disclose enough to allow reproducibility across scope
General claims without practical enabling info are invalid
Decision:
Some claims invalid due to insufficient disclosure
Significance:
Sufficiency requirement is crucial in biotech patents
Courts scrutinize experimental methods and reproducibility
3. Biologics & Data Exclusivity
Data exclusivity protects clinical trial data submitted to regulators to approve biologics and biosimilars.
Case 4: Amgen Inc v Sandoz Inc (US, 2017)
Facts:
Amgen sued Sandoz over biosimilar filgrastim, claiming patent infringement.
Legal Issue:
Application of Biologics Price Competition and Innovation Act (BPCIA)
Can biosimilar applicant rely on data exclusivity?
Court Reasoning:
Biosimilar applicants cannot launch before 12-year data exclusivity period ends
Patents and regulatory exclusivity are separate protections
Decision:
Sandoz cannot market biosimilar until exclusivity expired
Significance:
Strengthens US biologics data exclusivity protection
Biotech companies rely on regulatory data protection in addition to patents
Case 5: Generics (UK) Ltd v Novartis AG (UK, 2012)
Facts:
Dispute over generic imatinib (Gleevec) entry in UK market)
Legal Issue:
Does EU data exclusivity prevent generic launch even if patents expired?
Court Reasoning:
8+2 years data exclusivity rule applies (8 years no generic reliance, +2 years marketing)
IP rights and regulatory exclusivity enforceable separately
Decision:
Generic launch blocked until exclusivity period over
Significance:
EU strictly enforces data exclusivity
Distinct from patent rights, a crucial tool for pharma companies
4. Diagnostic & Method Patents
Diagnostics often rely on biomarkers, genetic tests, or methods of treatment.
Case 6: Mayo Collaborative Services v Prometheus Laboratories, Inc. (US, 2012)
Facts:
Prometheus patented methods for measuring metabolites to adjust drug dosage
Legal Issue:
Are medical diagnostic methods patentable or merely natural laws?
Court Reasoning:
Methods based on natural correlations are not patentable
Only innovative technical applications qualify
Decision:
Patents invalidated
Significance:
Restricts patenting of natural law-based diagnostic methods
Encourages technical innovation beyond discovery of biomarkers
Case 7: Eli Lilly v Human Genome Sciences (US, 2010)
Facts:
Dispute over patent on gene sequences predicting disease risk
Legal Issue:
Patent scope over gene-derived diagnostics
Decision:
Patents valid for synthetic sequences, invalid for natural sequences
Clarified scope of biotech method patents
Significance:
Reinforces distinction between discovery vs invention in biotech
5. Plant Biotechnology & GMOs
Case 8: Monsanto Technology LLC v Cefetra BV (CJEU, 2010)
Facts:
Unauthorized import of GM soybean shipments containing patented technology
Legal Issue:
Can patent rights enforce against imported commodities
Court Reasoning:
Patent rights extend to use, sale, and import of patented GMO seeds
Even indirect infringement is actionable
Decision:
Patent infringement confirmed
Significance:
EU recognizes strong enforcement rights for biotech crop patents
Sets precedent for cross-border biotech IP enforcement
6. Key Takeaways
| Topic | Legal Principle | Case Example |
|---|---|---|
| Gene patenting | Natural genes unpatentable; cDNA patentable | Myriad Genetics v AMP |
| Higher life forms | Jurisdictional limits on patenting animals | Harvard OncoMouse |
| Sufficiency | Patent must enable skilled person | Biogen v Medeva |
| Biologics & data exclusivity | 12-year US, 10-year EU (8+2) protection | Amgen v Sandoz, Generics v Novartis |
| Diagnostic methods | Natural laws not patentable | Mayo v Prometheus |
| GMOs & plant biotech | Strong cross-border enforcement | Monsanto v Cefetra |
7. Conclusion
IP in biotech & life sciences is complex because:
Patents must demonstrate human ingenuity
Data exclusivity protects investment beyond patents
Diagnostics and natural correlations face strict limits
Enforcement can be cross-border and involve both patents and regulatory protections
Companies must adopt multi-layered IP strategies combining:
Patents (composition, methods, biotech inventions)
Regulatory exclusivity (data exclusivity for drugs/biologics)
Trade secrets for manufacturing processes
Careful monitoring of global jurisdictions
RELATED Blog
comments